All Posts Tagged With: "SNY"
(TEVA) Teva Pharmaceutical Industries Active on the Generics Front
Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic...
(PRGO) Perrigo Analyst Maintains Neutral Share rating
We have maintained our Neutral rating on Perrigo Company (PRGO) with a target price of $100.00 following appraisal of second quarter of fiscal 2012 results.
Perrigo reported second quarter EPS of $1.20,...
(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain...
(VPHM) ViroPharma Drug Earns Priority Review
ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s...
(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(BMY) Bristol-Myers Squibb Sees Pipeline Setback
Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a...
(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress
Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA),...
(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results.
Micromet’s third quarter 2011 loss per share...
(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well.
Until recently, most commercialization efforts were focused on the U.S....
(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic...
(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral
We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic...
(PRGO) Perrigo Beats Earnings Forecast – Sales Miss
Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales...
(AMLN) Amylin Pharmaceuticals Posts Lower Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher...
(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals
Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals...
(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
(BMY) Bristol-Myers Squibb Presents HCV Data
Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care)...
(AZN) AstraZeneca’s Brilinta Now in US
AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular...
(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201)...
(BAC) Company News for September 12, 2011 – Corporate Summary
• Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) posted second quarter 2011 earnings of $0.38 per share, which surpassed the Zacks Consensus Estimate of $0.32
12Sep2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(MITI) Micromet Loss Less Than Analyst Estimates – Revenues Rise
Micromet Inc.’s (MITI) second quarter 2011 loss per share came in at 19 cents (after adjusting for the change in fair value of warrants), wider than the year-ago loss of 15 cents per share (also adjusting...
(VRX) Valeant Pharmaceuticals International Beats Expectations – Ups View
Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate...
(BMY) Bristol-Myers Squibb Company Reports Solid Quarter
Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues...
(REGN) Regeneron Pharmaceuticals Gets Mixed Data for REGN88
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi Aventis (SNY) recently announced data from two mid-stage studies of their pipeline...
(PRGO) Perrigo Downgraded to Neutral
We recently moved to a Neutral rating on Perrigo Company (PRGO) from Outperform. Our target price on the stock is $94.00.
Perrigo’s broad line of store brand pharmaceutical products has the same...
(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral
We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share.
We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first...
(JNJ) Boost for Bayer and Johnson & Johnson
Recently, the US Food and Drug Administration (FDA) delivered a huge boost for Bayer (BAYRY) and partner Johnson & Johnson (JNJ) by...
(NVO) Novo Nordisk Presents Late Stage Degludec Data
Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low...
(BMY) Bristol-Myers Squibb Expands HIV Drug’s Reach
Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir...